Bicycle Therapeutics Plc ADR (BCYC) Stock Price, Quote & News

Company Profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expr...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 1223 261 503

Website: www.bicycletherapeutics.com

Address:

Portway Building, Blocks A & B Granta Park Great Abington, Cambridge, United Kingdom

Peterson28 Jun. 15 at 11:57 PM

$BCYC Some funds dumped 2-3M shares today. Huge volume.

2 · Reply

US_Bull Jun. 15 at 8:06 PM

$BCYC 3 million shares traded >9x daily average and this board is absoflutely sleeping lol.

0 · Reply

US_Bull Jun. 15 at 4:34 PM

$BCYC Somebody is accumulating en masse!!

0 · Reply

US_Bull Jun. 15 at 4:32 PM

$BCYC Ignore the manipulation instead look at the volume once again surging at >1.5 million!!!

0 · Reply

eladfff Jun. 14 at 6:01 PM

$BCYC Looks terrible on every single timeframe, from 5-minute all the way to monthly candles. Those wanting out continue to throw more weight than anyone wanting in, even all the way down here at $4. Amazing. One of the Bakers' biggest misses ever, putting $600M+ into Kevin Lee and Co's hands at $21.50+/sh.

0 · Reply

LabPsycho Jun. 10 at 7:52 PM

$PBLS looks a lot like $BCYC to me when it came out years ago - then drifted down for years.

0 · Reply

US_Bull Jun. 9 at 6:34 PM

$BCYC Wow dead board nothing for a week I like finding these gems that are under the radar of retail only 945 followers before they start pouring in.

1 · Reply

US_Bull Jun. 9 at 5:33 PM

$BCYC Tons of volume pouring in.

0 · Reply

US_Bull Jun. 9 at 4:29 PM

$BCYC Appears catalysts coming up in H2. I saw that Bakers average is 21$ I like it down here.

0 · Reply

US_Bull Jun. 9 at 4:13 PM

$BCYC Actually just did 8,625 long shares I see value here. Selling is way overdone trading at half the cash position and impressive pipeline.

0 · Reply

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

2026-04-30T19:56:40.000Z - 7 weeks ago

Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies

2026-04-30T13:11:20.000Z - 7 weeks ago

Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c)

Apr 30, 2026, 7:00 AM EDT - 7 weeks ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Apr 30, 2026, 7:00 AM EDT - 7 weeks ago

Bicycle Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 7 weeks ago

Bicycle Therapeutics Earnings release: Q1 2026

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Bicycle Therapeutics Proxy statement: Proxy filing

Apr 21, 2026, 10:31 AM EDT - 2 months ago

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

2026-04-20T12:07:18.000Z - 2 months ago

Bicycle Therapeutics announces updates from EphA2 pipeline at AACR meeting

Apr 20, 2026, 7:00 AM EDT - 2 months ago

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

2026-04-08T11:55:49.000Z - 2 months ago

Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley

Apr 3, 2026, 8:00 AM EDT - 2 months ago

Bicycle Therapeutics Proxy statement: Proxy filing

2026-03-18T11:57:07.000Z - 3 months ago

Bicycle Therapeutics price target lowered to $7 from $11 at RBC Capital

2026-03-18T11:45:12.000Z - 3 months ago

Bicycle Therapeutics price target lowered to $36 from $44 at Oppenheimer

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

2026-03-18T09:40:52.000Z - 3 months ago

Bicycle Therapeutics price target lowered to $8 from $12 at Citizens

2026-03-17T16:05:50.000Z - 3 months ago

Bicycle Therapeutics price target lowered to $8 from $10 at Truist

2026-03-17T11:08:46.000Z - 3 months ago

Bicycle Therapeutics reports Q4 EPS (29c), consensus (95c)

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Bicycle Therapeutics Earnings release: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Bicycle Therapeutics Annual report: Q4 2025

2026-02-03T12:26:35.000Z - 4 months ago

Bicycle Therapeutics CFO Alethia Young steps down, Travis Thompson succeeds

2026-02-03T12:25:21.000Z - 4 months ago

Bicycle Therapeutics CMO Eric Westin retires, Michael Method succeeds

2026-02-03T12:25:14.000Z - 4 months ago

Bicycle Therapeutics names Michael Skynner chief scientific officer

Feb 3, 2026, 7:00 AM EST - 4 months ago

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

Jan 12, 2026, 7:00 AM EST - 5 months ago

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

Jan 12, 2026, 7:00 AM EST - 5 months ago

Bicycle Therapeutics Slides: Investor presentation

Dec 16, 2025, 1:00 AM EST - 6 months ago

Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline

2025-11-24T12:35:26.000Z - 7 months ago

Bicycle Therapeutics initiated with a Hold at Truist

Nov 18, 2025, 5:30 AM EST - 7 months ago

Bicycle Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 7 months ago

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

2025-10-31T10:00:15.000Z - 8 months ago

Bicycle Therapeutics price target raised to $12 from $10 at Citizens JMP

2025-10-31T09:25:16.000Z - 8 months ago

RBC downgrades Bicycle Therapeutics on slow pipeline progress

2025-10-31T01:15:14.000Z - 8 months ago

Bicycle Therapeutics downgraded to Sector Perform at RBC Capital

2025-10-30T11:50:32.000Z - 8 months ago

Bicycle Therapeutics reports Q3 EPS (85c), consensus ($1.07)

Oct 30, 2025, 7:00 AM EDT - 8 months ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Oct 30, 2025, 7:00 AM EDT - 8 months ago

Bicycle Therapeutics Earnings release: Q3 2025

Oct 30, 2025, 7:00 AM EDT - 8 months ago

Bicycle Therapeutics Quarterly report: Q3 2025

Sep 9, 2025, 7:45 AM EDT - 10 months ago

Bicycle Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 4:05 PM EDT - 10 months ago

Bicycle Therapeutics Strengthens Board of Directors with New Appointments

2025-08-12T09:50:11.000Z - 11 months ago

Bicycle Therapeutics price target lowered to $10 from $22 at Citizens JMP

2025-08-11T13:10:57.000Z - 11 months ago

Bicycle Therapeutics price target raised to $27 from $25 at RBC Capital

Aug 8, 2025, 8:00 AM EDT - 11 months ago

Bicycle Therapeutics Registration statement: Registration Filing

Aug 8, 2025, 7:00 AM EDT - 11 months ago

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Aug 8, 2025, 7:00 AM EDT - 11 months ago

Bicycle Therapeutics Quarterly report: Q2 2025

Aug 8, 2025, 7:00 AM EDT - 11 months ago

Bicycle Therapeutics Earnings release: Q2 2025

Jul 2, 2025, 4:05 PM EDT - 1 year ago

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 22, 2025, 5:05 PM EDT - 1 year ago

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

May 1, 2025, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Quarterly report: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Earnings release: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Slides: Investor Presentation

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Bicycle Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 12:45 PM EDT - 1 year ago

Bicycle Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Bicycle Therapeutics Proxy statement: Proxy Filing

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Mar 4, 2025, 9:50 AM EST - 1 year ago

Bicycle Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Annual report: Q4 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Earnings release: Q4 2024

Feb 12, 2025, 10:00 AM EST - 1 year ago

Bicycle Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 5, 2025, 7:00 AM EST - 1 year ago

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 8:15 PM EST - 1 year ago

Bicycle Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Jan 12, 2025, 7:00 PM EST - 1 year ago

Bicycle Therapeutics Slides: Investor Presentation

Jan 9, 2025, 7:00 AM EST - 1 year ago

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 8:00 AM EST - 1 year ago

Bicycle Therapeutics Transcript: Status Update

Dec 13, 2024, 8:00 AM EST - 1 year ago

Bicycle Therapeutics Press release: Status Update

Dec 13, 2024, 8:00 AM EST - 1 year ago

Bicycle Therapeutics Slides: Status Update

Dec 12, 2024, 6:30 PM EST - 1 year ago

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Dec 10, 2024, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Nov 25, 2024, 5:30 PM EST - 1 year ago

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Nov 19, 2024, 5:30 AM EST - 1 year ago

Bicycle Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Quarterly report: Q3 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Earnings release: Q3 2024

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Bicycle Therapeutics Transcript: Status Update

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Bicycle Therapeutics Press release: Status Update

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

Sep 18, 2024, 11:30 AM EDT - 1 year ago

Bicycle Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Sep 4, 2024, 8:30 AM EDT - 1 year ago

Bicycle Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Aug 6, 2024, 7:05 AM EDT - 2 years ago

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

Aug 6, 2024, 7:00 AM EDT - 2 years ago

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

BSY MASS MLI NJR OFIX QBTS SMMT

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Earnings release: Q2 2024

Jul 22, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024

Jun 10, 2024, 1:20 PM EDT - 2 years ago

Bicycle Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 2 years ago

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

May 23, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing

May 23, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Slides: Investor Presentation

May 2, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

May 2, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Quarterly report: Q1 2024

May 2, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Earnings release: Q1 2024

Apr 24, 2024, 10:05 AM EDT - 2 years ago

Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Bicycle Therapeutics Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Bicycle Therapeutics Proxy statement: Proxy Filing

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Bicycle Therapeutics Proxy statement: Proxy Filing

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Bicycle Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 5, 2024, 4:35 PM EST - 2 years ago

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

Feb 20, 2024, 7:05 AM EST - 2 years ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 7:00 AM EST - 2 years ago

Bicycle Therapeutics Annual report: Q4 2023

Feb 20, 2024, 7:00 AM EST - 2 years ago

Bicycle Therapeutics Earnings release: Q4 2023

Feb 7, 2024, 7:00 AM EST - 2 years ago

Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 14, 2023, 8:00 AM EST - 2 years ago

Bicycle Therapeutics Transcript: R&D Day 2023

Dec 14, 2023, 8:00 AM EST - 2 years ago

Bicycle Therapeutics Press release: FY 2023

Dec 14, 2023, 7:00 AM EST - 2 years ago

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Nov 30, 2023, 7:00 AM EST - 2 years ago

Bicycle Therapeutics to Host R&D Day on December 14

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Bicycle Therapeutics Quarterly report: Q3 2023

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Bicycle Therapeutics Earnings release: Q3 2023

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

Oct 19, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer

Oct 19, 2023, 4:00 AM EDT - 2 years ago

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

Sep 12, 2023, 10:10 AM EDT - 3 years ago

Bicycle Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 11, 2023, 8:00 AM EDT - 3 years ago

Bicycle Therapeutics Transcript: Study Update

Sep 11, 2023, 8:00 AM EDT - 3 years ago

Bicycle Therapeutics Slides: Study Update

Sep 11, 2023, 7:00 AM EDT - 3 years ago

Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer

Peterson28 Jun. 15 at 11:57 PM

$BCYC Some funds dumped 2-3M shares today. Huge volume.

2 · Reply

US_Bull Jun. 15 at 8:06 PM

$BCYC 3 million shares traded >9x daily average and this board is absoflutely sleeping lol.

0 · Reply

US_Bull Jun. 15 at 4:34 PM

$BCYC Somebody is accumulating en masse!!

0 · Reply

US_Bull Jun. 15 at 4:32 PM

$BCYC Ignore the manipulation instead look at the volume once again surging at >1.5 million!!!

0 · Reply

eladfff Jun. 14 at 6:01 PM

0 · Reply

LabPsycho Jun. 10 at 7:52 PM

$PBLS looks a lot like $BCYC to me when it came out years ago - then drifted down for years.

0 · Reply

US_Bull Jun. 9 at 6:34 PM

$BCYC Wow dead board nothing for a week I like finding these gems that are under the radar of retail only 945 followers before they start pouring in.

1 · Reply

US_Bull Jun. 9 at 5:33 PM

$BCYC Tons of volume pouring in.

0 · Reply

US_Bull Jun. 9 at 4:29 PM

$BCYC Appears catalysts coming up in H2. I saw that Bakers average is 21$ I like it down here.

0 · Reply

US_Bull Jun. 9 at 4:13 PM

$BCYC Actually just did 8,625 long shares I see value here. Selling is way overdone trading at half the cash position and impressive pipeline.

0 · Reply

US_Bull Jun. 9 at 3:59 PM

$BCYC Come to daddy starting a position soon following the Baker Brothers money.

0 · Reply

eladfff Jun. 3 at 3:30 PM

$BCYC Chart looks horrific, looks headed to $3. Amazing. Utter disaster of mismanagement of resources and focus. Not sure why Kevin Lee gets to keep his job

1 · Reply

aquira Jun. 3 at 2:26 PM

$BCYC everyday ATL. Foookenn hell

0 · Reply

aquira Jun. 2 at 3:52 PM

$BCYC this turd has been falling without fail since December 2021 and never saw green since then. Pathetic. Wasted my money here

1 · Reply

Autolus_Freakk May. 27 at 11:31 AM

$BCYC This shit does nothing, watching paint dry.. mainly due to it being owned by institutions and hedge funds

2 · Reply

Orlandotrader May. 21 at 8:15 PM

$BCYC In with 1,000

0 · Reply

Orlandotrader May. 18 at 8:22 PM

$BCYC Half a BILLION in Cash. Do we have a PipeLine? Guess we find out at ASCO. Will take small position.

0 · Reply

NVDAMillionaire May. 13 at 9:46 PM

$BCYC Great piece that accurately captures BCYC's current position. So if you want to refresh your understanding of BCYC or learn about BCYC for the first time, this is essential reading. https://everyticker.com/quote/BCYC/analysis/bicycle-therapeutics-bcyc-a-50-cost-cut-and-pipeline-reset-create-high-stakes-asymmetry

0 · Reply

tiddyy May. 13 at 6:53 AM

$BCYC Time will come for this

0 · Reply

Biotech_Pharma_Investor Apr. 30 at 1:51 PM

$BCYC I think the selling here is overdone. Cash runway into 2030. Market cap << cash. Nice platform. If anything works out (which I believe it should) a seriour repricing will follow

1 · Reply

aquira Apr. 30 at 1:43 PM

$BCYC looks like there is no saving this stock

0 · Reply

tiddyy Apr. 28 at 9:20 AM

$BCYC $800 million+ on cash, Phase 1/2 showed promising data 4 out of 10 patients got their tumors reduced And an additional 3 out of 3 patients saw a reduction too who were not exposed to the toxin before I think they will be more of a push for peptides, US media has been pushing for these breakthroughs I think the deprioritizing of their previous lead drug while reduces the value of this company, this is completely oversold The drug did not fail - it just was not feasible when another drug in the market has better results and is from big pharma

1 · Reply

Market Cap	282.04M
Revenue (ttm)	72.59M
Net Income (ttm)	-218.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-301.64%
Debt to Equity Ratio	0.00

Volume	317,900
Avg Vol	450,890
Day's Range	N/A - N/A
Shares Out	69.81M
Stochastic %K	16%
Beta	1.54
Analysts	Strong Sell
Price Target	$12.11